文献速递慢性肾脏病

慢性肾脏病中盐皮质激素受体拮抗剂的剂量特异性网络荟萃分析

Dose-Specific Network Meta-Analysis of Mineralocorticoid Receptor Antagonists in CKD.
PubMed 文献 · Kidney Int Rep · 2026-09-17

该网络荟萃分析纳入32项随机对照试验(N=21,678),比较不同剂量盐皮质激素受体拮抗剂(MRA)与标准治疗在CKD患者中的疗效与安全性。结果显示所有MRA剂量节点均显著降低尿白蛋白/肌酐比值(UACR),螺内酯25 mg与非奈利酮20 mg的降蛋白尿效应相似,高钾血症风险相对增加但亚类间无一致差异。

要点

  • 所有评估的MRA剂量节点均显著降低UACR,降蛋白尿效应存在重叠。
  • 螺内酯25 mg与非奈利酮20 mg降低白蛋白尿的效应相似。
  • 高钾血症风险相对增加,但甾体与非甾体亚类间无一致差异。

核心结论

  • 甾体与非甾体MRA均与白蛋白尿降低相关,降蛋白尿效应存在实质性重叠。
  • 研究结果强调甾体MRA作为可及治疗选择的持续临床相关性,并支持在CKD中进一步开展头对头结局驱动试验。

研究设计与样本

  • 遵循PRISMA-2020指南的系统综述与贝叶斯网络荟萃分析(注册号CRD420251152929)。
  • 检索PubMed、Embase、Cochrane Library、Web of Science和Scopus,纳入评估MRA用于CKD的随机对照试验。
  • 共分析32项试验,总样本量N=21,678;比较MRA与标准治疗。

主要发现

  • 所有评估的MRA剂量节点均显著降低UACR,降蛋白尿效应存在重叠。
  • 螺内酯25 mg与非奈利酮20 mg与相似的 albuminuria 降低相关。
  • 各治疗均观察到eGFR轻度下降,与早期血流动力学适应一致,主要基于短期研究。
  • 高钾血症风险相对增加,但亚类间无一致差异。
  • 荟萃回归显示UACR降低与随访时长或基线eGFR无关联;高钾血症及其他不良事件在随访更长和基线eGFR更低时更频繁。

关键数值与推荐

  • 主要结局为UACR变化;次要结局包括eGFR变化、高钾血症和不良事件。
  • 使用贝叶斯网络荟萃分析比较MRA与标准治疗;荟萃回归探索基线eGFR和随访时长的效应修饰。

临床怎么用

  • 甾体MRA(如螺内酯25 mg)可作为非奈利酮的可及替代选择,但需监测高钾血症。
  • 随访时间更长和基线eGFR更低的患者不良事件风险更高,应加强监测。

局限性

  • 缺乏直接比较试验,结论基于网络荟萃分析。
  • eGFR轻度下降的观察主要基于短期研究,长期影响不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Mineralocorticoid receptor antagonists (MRAs) have reemerged as a key strategy for cardiorenal risk reduction after the success of finerenone in large trials. However, high costs have limited the global accessibility, raising a relevant question: whether widely available steroidal MRAs provide comparable efficacy and safety. In the absence of direct comparative trials, we performed a network meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses-2020 guidelines (CRD420251152929). METHODS: We searched PubMed, Embase, Cochrane Library, Web of Science, and Scopus for randomized controlled trials (RCTs) evaluating MRAs in chronic kidney disease (CKD). A Bayesian network meta-analysis compared MRAs with standard care. The primary outcome was change in urine albumin-to-creatinine ratio (UACR). Secondary outcomes included change in estimated glomerular filtration rate (eGFR), hyperkalemia, and adverse events. Meta-regression explored effect modification by baseline eGFR and follow-up duration. RESULTS: A total of 32 trials (N = 21,678) were analyzed. All evaluated MRA dose nodes, which significantly reduced UACR, with overlapping antiproteinuric effects. Spironolactone 25 mg and finerenone 20 mg were associated with similar reductions in albuminuria. Mild reductions in eGFR were observed across treatments, consistent with early hemodynamic adaptation largely informed by short-term studies. Hyperkalemia risk relatively increased, without consistent differences between subclasses. Meta-regression showed no association between UACR reduction and follow-up duration or baseline eGFR. Hyperkalemia and other adverse events were more frequent with longer follow-up and lower baseline eGFR. CONCLUSION: Both steroidal and nonsteroidal MRAs were associated with reductions in albuminuria, with substantial overlap in antiproteinuric effects. Our findings underscore the continuing clinical relevance of steroidal MRAs as accessible therapeutic options and support further head-to-head outcome-driven trials in CKD.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Korucu B, Colak A, Mustafa R, et al. Dose-Specific Network Meta-Analysis of Mineralocorticoid Receptor Antagonists in CKD. Kidney Int Rep. 2026. PMID: 42965115. doi:10.1016/j.ekir.2026.107084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。